儿童及特应性皮炎人群皮肤化妆品阶梯式开发方法
本文提出一种针对儿童皮肤化妆品的阶梯式开发方法,依次进行体外成分安全性评估、临床前及临床评价(ROAT、HRIPT、成人/健康儿童/患儿使用耐受性研究),并结合上市后监测。以一款用于儿童特应性皮炎预防/维持的皮肤化妆品为例,表明该方法可降低敏感人群刺激和接触性皮炎风险。
要点
- 儿童皮肤化妆品开发应优先确保耐受性和安全性。
- 阶梯式方法包括体外评估、ROAT、HRIPT及分阶段使用耐受性研究。
- 该方法可降低敏感儿童人群的刺激和接触性皮炎风险。
核心结论
- 需要标准化的伦理阶梯式开发方法,以确保儿童皮肤化妆品安全且耐受性良好。
研究设计与样本
- 本文提出针对儿童皮肤化妆品的阶梯式开发方法,包括体外成分安全性评估、临床前和临床评价,以及临床开发和上市后监测。
主要发现
- 以一款用于儿童特应性皮炎预防/维持治疗的皮肤化妆品为例,使用该阶梯式方法测试产品可降低敏感人群的刺激和接触性皮炎潜在风险。
关键数值与推荐
- 阶梯式方法依次包括:体外成分安全性评估、ROAT、HRIPT、使用中皮肤科和眼科耐受性研究(3a健康成人、3b健康儿童、3c儿童患者)。
临床怎么用
- 该阶梯式方法可潜在作为新儿童化妆品评估的指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Paediatric skin, considered sensitive, and infant skin, more susceptible to percutaneous toxicity, require specially formulated cosmetic products. As recently shown, early use of emollients in infants "at risk" of developing atopic dermatitis has shown controversial results in reducing the incidence of atopic dermatitis. Development of dermo-cosmetic products for this specific population should especially ensure tolerance and safety. In absence of good clinical practice guideline, we propose here a stepwise approach for the development of paediatric cosmetic skincare products. METHODS: Our stepwise methodology for cosmetics aimed at paediatrics, starts with in vitro assessment of product's ingredients safety, followed by preclinical and clinical evaluations of the final product, including sequentially: (1) Repeated Open Application Test (ROAT), (2) Human Repeated Insult Patch Test (HRIPT), (3) In-use dermatological and ophthalmological tolerance studies (sequentially in 3a: healthy adults, 3b: healthy paediatric subjects and finally 3c: paediatric patients). We also describe the integrated cosmetovigilance-toxicological surveillance during the clinical development phase and postmarketing. RESULTS: As illustrated with one dermo-cosmetic product intended to be used as a preventative/maintenance treatment for atopic dermatitis in paediatric population, we show that using this stepwise methodology to test a product reduces potential risks of irritation and contact dermatitis in this sensitive population. CONCLUSION: Standardized ethical stepwise development approach is needed to ensure the commercialization of safe and well-tolerated dermo-cosmetics for paediatrics. The approach described here could potentially serve as guidance for evaluation of new paediatric cosmetic products.
引用
- Ribet V, Gurdak M, Ferret PJ, et al. Stepwise approach of development of dermo-cosmetic products in healthy and atopic dermatitis paediatric population: safety evaluation, clinical development and postmarket surveillance. J Eur Acad Dermatol Venereol. 2019. PMID: 31287596. doi:10.1111/jdv.15785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。